Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSYCHED-PAL: Psilocybin Microdose for Psychological Distress in Palliative Care
NCT07063862Phase 3Recruiting
- Sponsor
- Bruyère Health Research Institute
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psychological distress comparing Psilocybin Microdosing with Placebo (2 arms). Primary endpoint: Patient Global Impression of Change at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
psychological distress
Beyond the preview
Go deeper on NCT07063862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063862.